DK2767292T3 - Vedvarende lokalbedøvelsessammensætning indeholdende saib - Google Patents

Vedvarende lokalbedøvelsessammensætning indeholdende saib Download PDF

Info

Publication number
DK2767292T3
DK2767292T3 DK14167954.8T DK14167954T DK2767292T3 DK 2767292 T3 DK2767292 T3 DK 2767292T3 DK 14167954 T DK14167954 T DK 14167954T DK 2767292 T3 DK2767292 T3 DK 2767292T3
Authority
DK
Denmark
Prior art keywords
composition
bupivacaine
anesthetic
present
amount
Prior art date
Application number
DK14167954.8T
Other languages
English (en)
Inventor
Neil A Verity
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of DK2767292T3 publication Critical patent/DK2767292T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Detergent Compositions (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Selective Calling Equipment (AREA)

Claims (15)

1. Flydende sammensætning til tilvejebringelse af vedvarende lokalbedøvelse efter administration til et individ, hvilken sammensætning omfatter bupivacain som et bedøvelsesmiddel, sucroseacetatisobutyrat som en farmaceutisk acceptabel ikke-polymerbærer og benzylalkohol som et opløsningsmiddel for bæreren, hvor bupivacain er til stede i en mængde fra 30 til 5 vægt-% i forhold til sammensætningens samlede vægt
2. Sammensætning ifølge krav 1, hvor bupivacain er til stede i form af fri base.
3. Sammensætning ifølge krav 1 eller 2, hvor bæreren er til stede i en mængde fra 75 til 25 vægt-% i forhold til sammensætningens samlede vægt.
4. Sammensætning ifølge et hvilket som helst af de foregående krav, hvor opløsningsmidlet er til stede i en mængde fra 55 til 10 vægt-% i forhold til sammensætningens samlede vægt.
5. Sammensætning ifølge krav 4, hvor opløsningsmidlet er til stede i en mængde fra 50 til 15 vægt-% i forhold til sammensætningens samlede vægt.
6. Sammensætning ifølge et hvilket som helst af de foregående krav, hvor bupivacain er til stede i en mængde på fra 25 til 5 vægt-% i forhold til sammensætningens samlede vægt eller i en mængde på fra 20 til 5 vægt-% i forhold til sammensætningens samlede vægt.
7. Anvendelse af bupivacain som et bedøvelsesmiddel, sucroseacetatisobutyrat som en farmaceutisk acceptabel ikke-polymerbærer og benzylalkohol som et opløsningsmiddel for bæreren til fremstilling af en flydende sammensætning til tilvejebringelse af vedvarende lokalbedøvelse efter administration til et individ, hvor bupivacain er til stede i en mængde fra 30 til 5 vægt-% i forhold til sammensætningens samlede vægt.
8. Anvendelse ifølge krav 7, hvor sammensætningen administreres til et operationssår, og fortrinsvis hvor sammensætningen administreres i og/eller i umiddelbar nærhed af såret.
9. Anvendelse ifølge krav 7 eller 8, hvor sammensætningen administreres ved hældning.
10. Anvendelse ifølge et hvilket som helst af kravene 7 til 9, hvor individet er en menneskepatient, der opereres for lyskebrok.
11. Anvendelse ifølge et hvilket som helst af kravene 7 til 10, hvor sammensætningen anvendes til at behandle postoperativ smerte i forbindelse med en medicinsk behandling, hvor den medicinske behandling fortrinsvis er en appendektomi.
12. Anvendelse ifølge et hvilket som helst af kravene 7 til 11, hvor bupivacain er til stede i form af fri base.
13. Anvendelse ifølge et hvilket som helst af kravene 7 til 12, hvor bæreren er til stede i en mængde fra 75 til 25 vægt-% i forhold til sammensætningens samlede vægt.
14. Anvendelse ifølge et hvilket som helst af kravene 7 til 13, hvor opløsningsmidlet er til stede i en mængde fra 55 til 10 vægt-% i forhold til sammensætningens samlede vægt eller i en mængde fra 50 til 15 vægt-% i forhold til sammensætningens samlede vægt.
15. Anvendelse ifølge et hvilket som helst af kravene 7 til 14, hvor bupivacain er til stede i en mængde på fra 25 til 5 vægt-% i forhold til sammensætningens samlede vægt eller i en mængde på fra 20 til 5 vægt-% i forhold til sammensætningens samlede vægt.
DK14167954.8T 2004-09-17 2005-09-15 Vedvarende lokalbedøvelsessammensætning indeholdende saib DK2767292T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61079704P 2004-09-17 2004-09-17
US69139505P 2005-06-17 2005-06-17
EP20110187311 EP2415484B1 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing SAIB

Publications (1)

Publication Number Publication Date
DK2767292T3 true DK2767292T3 (da) 2016-12-19

Family

ID=35949130

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11187311T DK2415484T3 (da) 2004-09-17 2005-09-15 Sammensætning indeholdende saib til vedvarende lokalbedøvelse
DK05812735.8T DK1809329T3 (da) 2004-09-17 2005-09-15 Vedvarende lokalanæstesisammensætning indeholdende saib
DK14167954.8T DK2767292T3 (da) 2004-09-17 2005-09-15 Vedvarende lokalbedøvelsessammensætning indeholdende saib

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK11187311T DK2415484T3 (da) 2004-09-17 2005-09-15 Sammensætning indeholdende saib til vedvarende lokalbedøvelse
DK05812735.8T DK1809329T3 (da) 2004-09-17 2005-09-15 Vedvarende lokalanæstesisammensætning indeholdende saib

Country Status (26)

Country Link
US (9) US8753665B2 (da)
EP (4) EP2767292B1 (da)
JP (2) JP5285275B2 (da)
KR (2) KR101492361B1 (da)
AT (1) ATE537844T1 (da)
AU (1) AU2005287175B2 (da)
BR (1) BRPI0515372B8 (da)
CA (1) CA2581287C (da)
CY (2) CY1112625T1 (da)
DK (3) DK2415484T3 (da)
EA (2) EA201001885A1 (da)
ES (3) ES2602273T3 (da)
GE (1) GEP20094831B (da)
HK (1) HK1201437A1 (da)
HR (1) HRP20120254T1 (da)
HU (1) HUE032040T2 (da)
IL (1) IL181474A (da)
LT (1) LT2767292T (da)
MX (1) MX2007002962A (da)
NO (1) NO342596B1 (da)
NZ (1) NZ553369A (da)
PL (2) PL2415484T3 (da)
PT (3) PT2767292T (da)
RS (1) RS52198B (da)
SI (2) SI2767292T1 (da)
WO (1) WO2006033948A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
WO2006039336A2 (en) * 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
ES2388355T3 (es) * 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
PL3085363T3 (pl) * 2007-03-28 2019-08-30 Innocoll Pharmaceuticals Limited Urządzenie dostarczające lek dla zapewnienia miejscowej analgezji, miejscowego znieczulenia lub blokady nerwowej
EP2244679A4 (en) * 2008-02-08 2013-10-09 Qps Llc NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
US9045600B2 (en) 2009-05-13 2015-06-02 Keraplast Technologies, Ltd. Biopolymer materials
MX347014B (es) * 2010-11-24 2017-04-07 Durect Corp Composición para administración de fármaco biodegradable.
US10828272B2 (en) * 2012-05-16 2020-11-10 Chardon Group B.V. Means to facilitate food intake and food retention
WO2014143635A1 (en) 2013-03-15 2014-09-18 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
CA2913100C (en) * 2013-05-24 2021-10-26 Danmarks Tekniske Universitet Gel formulations for guiding radiotherapy
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2015123734A1 (en) * 2014-02-21 2015-08-27 The University Of Sydney Liquid carrier materials
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
CN106535886A (zh) 2014-04-21 2017-03-22 赫伦治疗有限公司 长效聚合物输送系统
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
KR20170025011A (ko) 2015-08-27 2017-03-08 고려대학교 산학협력단 통증완화약물의 지속성 방출을 위한 약학적 조성물 및 그 투여를 위한 투여 장치
WO2017193066A1 (en) * 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Precision controlled load and release particles for post-operative pain
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
US10668011B2 (en) * 2016-06-30 2020-06-02 Durect Corporation Depot formulations
US11000487B2 (en) * 2016-12-26 2021-05-11 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
PL3486233T3 (pl) * 2017-03-27 2021-06-28 Fruithy Holdings Limited Słabo rozpuszczalny kompleks lub jego solwat, kompozycja farmaceutyczna i jej zastosowanie
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
RU2674025C1 (ru) * 2017-10-25 2018-12-04 Общество с ограниченной ответственностью "Научно-производственная фирма "ЭЛЕСТ" (ООО "НПФ "ЭЛЕСТ") Лекарственное средство на основе порфиринового фотосенсибилизатора копропорфирина для лечения рака кожи методом фотодинамической терапии
EP4087540A4 (en) * 2020-01-06 2024-01-10 Pacira Pharmaceuticals, Inc. TREATMENT OF PAIN ASSOCIATED WITH CESAREON SECTION USING SUSTAINED RELEASE LIPOSOMAL ANESTHETICS COMPOSITION
CN115297854A (zh) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛
EP4087568A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals, Inc. TREATMENT OF PAIN BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHESIC COMPOSITIONS
CN115666621A (zh) * 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3168712A1 (en) * 2020-02-25 2021-09-02 The University Of North Carolina At Chapel Hill Eutectic based anesthetic compositions and applications thereof
US11918688B2 (en) 2021-01-11 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
CN115068414B (zh) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
CN117320696A (zh) 2021-03-19 2023-12-29 帕西拉制药股份有限公司 通过给予缓释脂质体麻醉组合物治疗儿科患者的疼痛
CN115414324A (zh) * 2021-05-31 2022-12-02 中国科学院过程工程研究所 一种载局部麻醉药的乳剂及其制备方法
IL314565A (en) 2022-01-28 2024-09-01 Rebel Medicine Inc Pharmaceutical preparations for pain treatment
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556450A (en) * 1896-03-17 Antifriction-bearing
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
GB1088992A (en) 1963-09-19 1967-10-25 Squibb & Sons Inc Protective dressings
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3743398A (en) 1971-03-22 1973-07-03 Eastman Kodak Co Motion picture projector
NO139560C (no) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
DE2451841A1 (de) 1973-11-01 1975-05-07 Wellcome Found Biologisch aktive amide, verfahren zu ihrer herstellung und ihre verwendung
DE2438352A1 (de) 1974-08-09 1976-02-26 Hoechst Ag Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
NZ194405A (en) 1979-08-02 1982-05-25 Dut Pty Ltd Producing liquid hydrocarbon streams by hydrogenation of fossil-based feedstock
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
DE3716302C2 (de) 1987-05-15 1996-02-01 Henkel Kgaa Verbesserte resorbierbare Knochenwachse und ihre Verwendung
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS59210024A (ja) 1983-05-13 1984-11-28 Taiyo Kagaku Kk トコフエロ−ル乳化物
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS607418U (ja) 1983-06-28 1985-01-19 株式会社デンソー 歯付スラストワツシヤをもつ軸受装置
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4630019A (en) 1984-09-28 1986-12-16 Westinghouse Electric Corp. Molded case circuit breaker with calibration adjusting means for a bimetal
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
ATE107857T1 (de) 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4795641A (en) 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5110685A (en) 1990-05-18 1992-05-05 Exxon Chemical Patents, Inc. Low friction, abrasion resistant polymer coating
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992017900A1 (en) 1991-04-03 1992-10-15 Eastman Kodak Company HIGH DURABILITY MASK FOR DRY ETCHING OF GaAs
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
DE69231536T2 (de) 1991-08-26 2001-06-13 Abbott Laboratories, Abbott Park Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
IL103275A0 (en) 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3313113B2 (ja) 1991-10-21 2002-08-12 ペプテック リミテッド 雌馬の排卵制御用生体適合性インプラント
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
DE69212497T2 (de) 1991-12-05 1996-12-12 Mallinckrodt Veterinary, Inc., Mundelein, Ill. Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
EP0616526A1 (en) 1991-12-11 1994-09-28 The Procter & Gamble Company Cetylpyridinium chloride and domiphen bromide in organic solvent
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5540912A (en) 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
ES2170074T3 (es) 1992-09-10 2002-08-01 Childrens Medical Center Matrices de polimero biodegradables para la liberacion prolongada de agentes anestesicos locales.
CA2150574A1 (en) 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
AU679510B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
DE69413955T2 (de) 1993-03-17 1999-04-01 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
DK44193D0 (da) 1993-04-20 1993-04-20 Euromed I S Saarforbinding og klaebemiddel til en saarforbinding eller lignende
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
JP3257750B2 (ja) 1993-07-20 2002-02-18 エチコン・インコーポレーテツド ε−カプロラクトンおよびラクチドの液状コポリマー
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
JPH07112940A (ja) 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
AU5895994A (en) 1993-10-04 1995-05-01 Mark Chasin Controlled release microspheres
CA2180260A1 (en) 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
PT782569E (pt) 1994-09-23 2002-09-30 Darwin Discovery Ltd Processo de racemizacao utilizado no fabrico de levobupivacaina e seus analogos
US5599852A (en) 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
DE69531356T2 (de) 1994-10-25 2004-05-27 Darwin Discovery Ltd., Slough Kristallisierung von levobupivacaine und deren analogen
ES2203645T3 (es) 1994-10-25 2004-04-16 Darwin Discovery Limited Procedimiento para la preparacion de levobupivacaina y analogos de losmismos.
GB9501071D0 (en) 1995-01-18 1995-03-08 Chiroscience Ltd Racemisation
US6384227B2 (en) 1995-01-18 2002-05-07 Darwin Discovery Ltd. Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
ATE287673T1 (de) 1995-06-07 2005-02-15 Southern Biosystems Inc Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
CA2195119C (en) 1995-06-09 2001-09-11 Mark Chasin Formulations and methods for providing prolonged local anesthesia
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
ATE303792T1 (de) 1996-02-02 2005-09-15 Alza Corp Implantierbares system mit verzögerter wirkstofffreisetzung
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
EP0954301A4 (en) 1996-06-24 2006-03-08 Euro Celtique Sa SAFE METHODS OF LOCAL ANESTHESIA
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DE19714765A1 (de) 1997-04-10 1998-10-15 Merck Patent Gmbh Verwendung von niedermolekularen, oligomeren Estern von alpha-Hydroxysäuren und/oder aromatischen o-Hydroxysäuren in kosmetischen Formulierungen
US5919473A (en) 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
BR9814883A (pt) 1997-11-19 2000-10-03 Darwin Discovery Ltd Formulação anestésica
RU2180557C2 (ru) * 1998-06-26 2002-03-20 Казахский Государственный национальный университет им. Аль-Фараби Анестезирующий состав пролонгированного действия
PL345216A1 (en) 1998-06-29 2001-12-03 Pharmaceuticals Applic Asociat Methods and transdermal compositions for pain relief
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
DE19858891A1 (de) 1998-12-19 2000-06-21 Merck Patent Gmbh Verbesserte Knochensiegel
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
NZ515644A (en) * 1999-06-04 2004-12-24 Skyepharma Inc Oil-core compositions for the sustained release of hydrophobic drugs
WO2000078335A1 (en) 1999-06-18 2000-12-28 Southern Biosystems, Inc. COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
PT1248596E (pt) 2000-01-11 2007-06-21 Bertex Pharma Gmbh Kit para implantações contendo uma fase de veículo e um solvente
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
FR2814308B1 (fr) 2000-09-15 2003-03-14 France Telecom Procede de gestion de l'usage d'une ligne de telecommunication et systeme de mise en oeuvre
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク,エス.エイ. ヒドロコドン放出制御製剤
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
ES2554106T3 (es) 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
FR2838349B1 (fr) 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
WO2003101358A1 (en) 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20040109893A1 (en) 2002-06-25 2004-06-10 Guohua Chen Sustained release dosage forms of anesthetics for pain management
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP4417039B2 (ja) 2002-06-28 2010-02-17 太陽化学株式会社 水中油滴型乳化組成物
JP4712380B2 (ja) 2002-07-26 2011-06-29 三笠製薬株式会社 外用剤
AU2003267763A1 (en) 2002-10-25 2004-05-13 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
AU2003267788A1 (en) 2002-10-25 2004-05-13 Pfizer Products Inc. Novel injectable depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
BR0317421A (pt) 2002-12-19 2005-11-08 Alza Corp Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável
DE10312346A1 (de) 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US20050106304A1 (en) 2003-11-14 2005-05-19 Cook Phillip M. Sucrose acetate isobutyrate formulation
US20050171052A1 (en) 2003-11-14 2005-08-04 Cook Phillip M. Sucrose acetate isobutyrate formulation
US20050232876A1 (en) 2004-04-19 2005-10-20 Robin Lynn Minga Skin care compositions
US20080023261A1 (en) 2004-05-14 2008-01-31 Yanmar Co., Ltd. Noise Proof Structure of Cabin
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
WO2006084141A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc Suspension formulation of interferon
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP5194273B2 (ja) 2007-09-20 2013-05-08 三菱電機株式会社 半導体装置
SE531980C2 (sv) 2008-01-17 2009-09-22 Avtech Sweden Ab Flygstyrningsförfarande samt datorprogram och datorprogramprodukt för att genomföra förfarandet

Also Published As

Publication number Publication date
PT1809329E (pt) 2012-03-29
NO20071914L (no) 2007-06-15
EP2415484A1 (en) 2012-02-08
HUE032040T2 (en) 2017-09-28
US20110009451A1 (en) 2011-01-13
US8153661B2 (en) 2012-04-10
US8846072B2 (en) 2014-09-30
US20080167630A1 (en) 2008-07-10
WO2006033948A3 (en) 2006-06-08
CA2581287C (en) 2015-08-25
NZ553369A (en) 2010-11-26
PT2767292T (pt) 2016-11-23
JP2009073839A (ja) 2009-04-09
US20090036490A1 (en) 2009-02-05
EP1809329B1 (en) 2011-12-21
AU2005287175B2 (en) 2011-12-01
SI2767292T1 (sl) 2017-01-31
BRPI0515372B1 (pt) 2020-10-06
JP5285275B2 (ja) 2013-09-11
ES2378671T3 (es) 2012-04-16
EP1809329A2 (en) 2007-07-25
KR20070059148A (ko) 2007-06-11
US8153149B2 (en) 2012-04-10
JP2008513467A (ja) 2008-05-01
KR101351771B1 (ko) 2014-02-17
US20190231762A1 (en) 2019-08-01
HK1201437A1 (en) 2015-09-04
GEP20094831B (en) 2009-11-25
US20130289069A1 (en) 2013-10-31
RS52198B (en) 2012-10-31
PL2415484T3 (pl) 2014-11-28
ES2496765T3 (es) 2014-09-19
WO2006033948A2 (en) 2006-03-30
US20160235726A1 (en) 2016-08-18
BRPI0515372A (pt) 2008-07-22
DK2415484T3 (da) 2014-09-22
LT2767292T (lt) 2016-12-12
NO342596B1 (no) 2018-06-18
CY1112625T1 (el) 2016-02-10
EA201001885A1 (ru) 2011-12-30
BRPI0515372B8 (pt) 2021-05-25
CY1118360T1 (el) 2017-06-28
HRP20120254T1 (hr) 2012-04-30
US8753665B2 (en) 2014-06-17
SI2415484T1 (sl) 2014-10-30
KR20130136595A (ko) 2013-12-12
US20170216267A1 (en) 2017-08-03
MX2007002962A (es) 2008-03-05
PT2415484E (pt) 2014-09-19
PL1809329T3 (pl) 2012-08-31
EA014852B1 (ru) 2011-02-28
US20180256553A1 (en) 2018-09-13
JP5285374B2 (ja) 2013-09-11
ATE537844T1 (de) 2012-01-15
EP2767292A1 (en) 2014-08-20
IL181474A0 (en) 2007-07-04
EP2415484B1 (en) 2014-06-18
AU2005287175A1 (en) 2006-03-30
EA200700653A1 (ru) 2007-10-26
CA2581287A1 (en) 2006-03-30
US20150111924A1 (en) 2015-04-23
ES2602273T3 (es) 2017-02-20
DK1809329T3 (da) 2012-04-02
IL181474A (en) 2014-05-28
KR101492361B1 (ko) 2015-02-11
EP3103477A1 (en) 2016-12-14
EP2767292B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
DK2767292T3 (da) Vedvarende lokalbedøvelsessammensætning indeholdende saib
RU2429882C2 (ru) Система контролируемой доставки
AU2012201226B2 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
AU2017228714A1 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB